Description

Product Description

Sorafenib Tosylate (CAS 284461-73-0) is an orally active, small-molecule multi-kinase inhibitor with potent activity against RAF kinases, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, and FLT-3. By targeting multiple kinases involved in cell proliferation and angiogenesis, Sorafenib provides researchers with a versatile tool for preclinical oncology and molecular signaling studies.

Mechanistically, Sorafenib inhibits the RAF/MEK/ERK pathway, reducing downstream transcriptional activation and cell proliferation in tumor models. In addition, VEGFR and PDGFR inhibition disrupts endothelial cell signaling, tube formation, and angiogenesis, making it suitable for studies of tumor vascularization and microenvironment modulation.

In preclinical models, Sorafenib Tosylate is employed to:

• Evaluate the role of RAF kinases in oncogenic signaling and tumor progression.

• Investigate VEGFR- and PDGFR-mediated angiogenesis and vascular remodeling.

• Assess combination therapy strategies with chemotherapeutics or other targeted inhibitors.

• Explore adaptive resistance mechanisms and kinase cross-talk.

Supplied as a white to off-white crystalline powder with ≥99% purity, Sorafenib Tosylate is stable under refrigerated conditions (2–8 °C) and soluble in DMSO, ethanol, and methanol. Each batch is verified using HPLC, MS, and NMR to ensure reproducibility and high purity for experimental research.

Sorafenib’s multi-target profile allows detailed mechanistic studies of receptor and intracellular kinase networks, cellular proliferation, apoptosis, and tumor microenvironment interactions. Researchers can examine downstream phosphorylation, transcriptional regulation, and compensatory signaling in response to multi-kinase inhibition. Its high selectivity and well-characterized activity profile make Sorafenib an indispensable reagent for translational research in oncology.

Product Specifications

Mechanism of Action

Sorafenib Tosylate functions as a multi-kinase inhibitor, targeting both intracellular and receptor kinases. It inhibits RAF kinases (CRAF, BRAF), disrupting the RAF/MEK/ERK signaling pathway, and also blocks VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β, suppressing angiogenesis.

This dual inhibition reduces tumor cell proliferation, promotes apoptosis, and limits vascularization in preclinical models. Researchers employ Sorafenib to study tumor growth, kinase signaling cross-talk, endothelial cell function, and mechanisms of resistance to multi-kinase inhibition.

Side Effects

For laboratory use, handle Sorafenib with standard safety precautions:

• Avoid inhalation, ingestion, and contact with skin or eyes.

• Use gloves, lab coat, and protective eyewear.

• Conduct experiments in a well-ventilated fume hood or biosafety cabinet.

• Dispose of waste according to institutional safety protocols.

Experimental effects may include altered cell proliferation, kinase signaling inhibition, or reduced angiogenesis in vitro or in vivo. This product is strictly for research use only.

Keywords

Sorafenib Tosylate, CAS 284461-73-0, multi-kinase inhibitor, RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, preclinical oncology research, angiogenesis studies, endothelial cell signaling, high purity, ≥99% purity, factory peptide supplier, peptide wholesale China, China peptide manufacturer, OEM & bulk peptide production.

Shipping Guarantee

All Sorafenib Tosylate shipments are handled with validated cold-chain logistics to maintain compound integrity. Lyophilized powder is sealed in moisture-proof, light-protected containers with secondary protective wrapping. Packages include full tracking and insurance coverage for safe delivery worldwide.

Trade Assurance

Sorafenib Tosylate Product authenticity is guaranteed and analytically verified using HPLC, MS, and NMR. Each batch includes a Certificate of Analysis (CoA) confirming ≥99% purity. Replacement or refund is provided for any deviation from listed specifications.

Payment Support

Accepted global payment options include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are encrypted and verified for security.

Disclaimer

This Sorafenib Tosylate product is intended for laboratory research use only. It is not for human or veterinary administration. Researchers must follow appropriate safety protocols. Data generated with Sorafenib should not be interpreted as clinical evidence or therapeutic guidance.

References

1. PubChem Database: Sorafenib Tosylate (CID 216239)

2. ChEMBL Database: Sorafenib Bioactivity Summary (ChEMBL ID CHEMBL1338)

3. DrugBank: Sorafenib – DB00398 (Mechanism and Pharmacology Data)

4. PubMed ID 15502804 – Sorafenib inhibits RAF/VEGFR in preclinical models

5. IUPHAR/BPS Guide to Pharmacology: Sorafenib target profile